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n recent years, much attention has been focused on anemia in patients with cancer and its effect on their healthrelated quality of life (QOL). Anemia is highly prevalent in patients with cancer, either as a result of the cancer itself or as a consequence of treatments, be they chemotherapy, radiation, or surgery (Groopman & Itri, 1999; Johnston & Crawford, 1998; Mercadante, Gebbia, Marrazzo, & Filosto, 2000; Tchekmedyian, 2002) . More than half of all patients with cancer may be affected by anemia (Gillespie, 2002; Johnston & Crawford) . In addition to myelosuppressive or nephrotoxic chemotherapy, underlying causes of anemia in patients with cancer include destruction or displacement of bone marrow, bleeding, nutritional defi ciencies, and chronic anemia of cancer (Erslev, 2000; Mercadante et al.) . Hemolytic anemia also may occur in lymphoproliferative disorders, such as chronic lymphocytic leukemia and lymphoma, because of the destruction of red blood cells (RBCs) through an inappropriate autoimmune response (Montserrat, Bosch, & Rozman, 1997) .
Anemia is associated with a range of debilitating symptoms, in particular fatigue (Cella, 1998 (Cella, , 2002 Curt, 2000; Holzner et al., 2002; Ludwig & Pecorelli, 2000) . Fatigue can have signifi cant effects on patients' QOL. For example, it can reduce a patient's ability to work and increase the assistance required from informal caregivers (Berndt et al., 2002) , such as family members or spouses. Fatigue also may result in considerable distress for patients. Of the most frequent symptoms reported by patients with cancer in a survey of those attending an ambulatory care center, lack of energy was cited as the most severe, and 50% of patients reported symptom distress related to their disease and treatment (Singer & Patel, 2002) . The negative effects of fatigue on QOL may be long-term. One study found that patients experiencing greater fatigue during chemotherapy for breast cancer had lower social functioning, vitality, and general health and more pain one year later (Byar & Berger, 2003) . In addition to fatigue, patients with anemia also may experience dizziness, headache, chest pain, shortness of breath, and decreased motivation (Cella, 1998) , all of which reduce well-being and affect the ability to continue with life as normal.
The high prevalence and impact of anemia in patients with cancer are especially of concern to those providing care and treatment. Despite the increasing evidence of the benefi ts of managing anemia, the condition still is under-recognized and undertreated in patients with cancer (Gillespie, 2002; Mock & Olsen, 2003) . Studies have suggested that more than half of patients with cancer-related anemia do not receive any treatment for it (Lawless, Wilson-Royalty, & Meyers, 2000; Ludwig, Birgegard, Barrett-Lee, & Krzakowski, 2002) . Oncology nurses are involved closely with symptom identifi cation and treatment planning. Nurses must not only understand the implications of anemia in patients with cancer, but also intervene on their behalf by raising awareness among patients and healthcare providers about the signifi cant impact of anemia on QOL and the need for appropriate monitoring. Educational resources now are more readily available to help healthcare providers achieve that goal (Buchsel, Murphy, & Newton, 2002) . Nurses also can help ensure that the care plan developed to manage patients' anemia addresses their needs and enables them to maximize their QOL.
Management options for anemia in patients with cancer currently include RBC transfusions and erythropoietic agents, such as recombinant human erythropoietin (rHuEPO) (e.g., epoetin alfa and epoetin beta [Procrit ® , Ortho Biotech Products, L.P., Bridgewater, NJ; NeoRecormon ® , F. Hoffman-La Roche Ltd., Basel, Switzerland]) or darbepoetin alfa (Aranesp ® , Amgen Inc., Thousand Oaks, CA). Because RBC transfusions are associated with several risks, including infection, immunosuppression, and adverse hemolytic reactions (Mercadante et al., 2000; Tchekmedyian, 2001) , patients may be reluctant to receive allogeneic transfusions (Lee et al., 1998) . Consequently, the use of erythropoietic agents is increasing in anemia management. However, a need exists for more convenient dosing schedules to minimize the frequency of clinic visits for patients requiring treatment for anemia. This review evaluates the evidence supporting the effectiveness of darbepoetin alfa administered every two weeks (Q2W) for the treatment of chemotherapy-induced anemia and its effects on health-related QOL.
Managing Chemotherapy-Induced Anemia With Erythropoietic Agents
Erythropoietic agents correct anemia by stimulating the production of RBCs (erythropoiesis) in the same way as endogenous human erythropoietin (EPO), the hormone that regulates erythropoiesis. EPO is produced primarily in the kidneys in response to hypoxia (Mercadante et al., 2000) . In patients with cancer, the number of RBC progenitor cells may be decreased, or a blunted response may exist to EPO or decreased EPO production relative to the degree of anemia (Erslev, 2000; Mercadante et al.; Miller, Jones, Piantadosi, Abeloff, & Spivak, 1990) . Erythropoietic therapy can restore RBC levels, thereby alleviating anemia and its symptoms and improving patients' QOL (Buchsel et al., 2002; Cella, 2002; Cleeland et al., 2003; Crawford et al., 2002; Demetri, Kris, Wade, Degos, & Cella, 1998; Gabrilove et al., 2001; Glaspy et al., 1997 Littlewood, Bajetta, Nortier, Vercammen, & Rapoport, 2001; Quirt et al., 2001; Vadhan-Raj et al., 2003) .
Although recent reports of clinical trials of epoetin alfa and epoetin beta have suggested that erythropoietic treatment may be associated with adverse outcomes in some patients (Henke et al., 2003; Leyland-Jones, 2003; Wun et al., 2003) , a large body of evidence supports the safe use of these agents. A three-times-weekly (TIW) schedule of epoetin alfa had been used widely because of the drug's relatively short halflife (four to eight hours) (Abels, 1993; Demetri et al., 1998; Glaspy et al., 1997; Kunikane et al., 2001; Littlewood et al., 2001; Ortho Biotech Products, L.P., 2000; Osterborg et al., 2002) . More recently, a weekly schedule of 40,000 U epoetin alfa was shown to be equally effective in patients with chemotherapy-induced anemia (Gabrilove et al., 2001 ) and now commonly is used in clinical practice in the United States (Rizzo et al., 2002) .
Darbepoetin alfa was approved by the U.S. Food and Drug Administration in July 2002 for the treatment of anemia in patients with nonmyeloid malignancies in which anemia is associated with concomitantly administered chemotherapy. Darbepoetin alfa is a unique erythropoietic agent that acts in the same way as endogenous EPO and rHuEPO but has an approximately threefold longer half-life than rHuEPO (Egrie, Dwyer, Browne, Hitz, & Lykos, 2003) , allowing less-frequent dosing (Amgen Inc., 2002) . Additionally, the longer half-life permits administration in a variety of schedules, including once weekly (QW) and Q2W (Glaspy & Tchekmedyian, 2002; Vadhan-Raj et al., 2003; Vansteenkiste et al., 2002) . Studies are under way to investigate the use of darbepoetin alfa every three weeks, and data so far suggest that this also is an effective regimen (Kotasek et al., 2003) . The Q2W dosing regimen, however, has been used in the largest number of patients in clinical studies (Vadhan-Raj et al.) and has been adopted widely in clinical practice (Boccia, Davidson, Tomita, Green, & Smith, 2003; Schwartzberg et al., 2003; Thames, Yao, Scheifele, & Alley, 2003) .
Hematologic Effects of Darbepoetin Alfa Administered
Every Two Weeks
Dose-Finding Studies
In a dose-fi nding study of darbepoetin alfa, a variety of QW and Q2W doses were evaluated . The study established that the minimum effective weekly dose of darbepoetin alfa is 1.5 mcg/kg. In addition, the study showed that the dosing interval of darbepoetin alfa could be extended from QW to Q2W with no requirement for an increased weekly dose (i.e., 3 mcg/kg Q2W was equivalent to 1.5 mcg/kg QW).
Weight-Based Dosing Studies
The largest study of darbepoetin alfa Q2W in the management of chemotherapy-induced anemia that has been published to date was an ongoing, 16-week, open-label, community-based study of 1,173 patients (Vadhan-Raj et al., 2003) . The study was designed to develop a screening tool to assess functional capacity in patients with nonmyeloid malignancies and anemia (hemoglobin < 11.0 g/dl) receiving chemotherapy. Patients currently receiving chemotherapy, with at least eight additional weeks of treatment planned, received darbepoetin alfa 3.0 mcg/kg Q2W for a total of eight doses (16 weeks of treatment and observation). After three doses, if hemoglobin levels had not increased by > 1.0 g/dl from baseline, the darbepoetin alfa dose was increased to 5.0 mcg/kg Q2W. In the interim analysis of this study, the hematologic effects of darbepoetin alfa were evaluated, and the relationship between hemoglobin level and patient-reported fatigue scores was investigated.
As shown in Figure 1 , hemoglobin increased over time during the study. The mean increase in hemoglobin from baseline to the end of treatment was 2.1 g/dl for patients who received the full 16 weeks of therapy. Seventy-one percent of patients had a hemoglobin response (an increase in hemoglobin of > 2.0 g/dl from baseline in the absence of an RBC transfusion), and 84% of patients had a hematopoietic response (hemoglobin response or hemoglobin correction to > 12.0 g/dl) during the treatment period (Kaplan-Meier estimates of proportion) (Vadhan-Raj et al., 2003) . Thus, the majority of patients treated with darbepoetin alfa Q2W experienced a correction of or clinically meaningful improvement in hemoglobin level.
Fixed-Dosing Studies
Early data from studies of patients treated in clinical practice and from clinical trial simulation suggest that a fi xed dose of darbepoetin alfa 200 mcg Q2W (equivalent to 3.0 mcg/kg based on an average patient weight of 70 kg) would be equally effective in most patients (Jumbe, Yao, Rovetti, Rossi, & Heatherington, 2002; Thames et al., 2003) . In a phase IV, open-label, community-based clinical study, anemic patients (hemoglobin < 11.0 g/dl) with nonmyeloid malignancies (N = 1,127) received darbepoetin alfa 200 mcg Q2W for as long as 24 weeks, with dose escalation to 300 mcg Q2W after four weeks if hemoglobin increased < 1.0 g/dl from baseline . In an interim analysis of data through week 13 of the study, 65% of evaluable patients achieved a hematopoietic response, and the incidence of RBC transfusions decreased by 40% from months 1 through 3. Several chart reviews also have confi rmed the effectiveness of this fi xed dose of darbepoetin alfa Q2W in clinical practice Schwartzberg et al., 2003) .
Measuring the Effects of Darbepoetin Alfa Given Every Two Weeks on Health-Related Quality of Life Fatigue
In addition to increasing patients' hemoglobin levels, treatment with darbepoetin alfa Q2W also can improve QOL. Fatigue, one of the most incapacitating symptoms of anemia, can be assessed using the Functional Assessment of Cancer Therapy-Fatigue (FACT-F) questionnaire (Cella, 1998; Yellen, Cella, Webster, Blendowski, & Kaplan, 1997) , which is administered to patients at baseline and during treatment with darbepoetin alfa. As part of the FACT-F, patients are asked to indicate how true statements such as "I feel fatigued," "I have energy," and "I need help doing my usual activities" were for them during the previous seven days.
The maximum score on the FACT-F is 52 points, which indicates that no fatigue is present. The average FACT-F score for the U.S. population is about 44 points, compared with an average of 40 points for the nonanemic cancer population and an average of 24 points for the anemic cancer population (Cella, Lai, Chang, Peterman, & Slavin, 2002) . In the large, community-based study of darbepoetin alfa (Vadhan-Raj et al., 2003) , the mean FACT-F score at baseline was 26 points. Cella, Eton, Lai, Peterman, and Merkel (2002) have established that an increase of more than three points on the FACT-F subscale represents a clinically important improvement in fatigue. In the Vadhan-Raj et al. study, after eight weeks of treatment with darbepoetin alfa (four doses), the mean FACT-F score had increased by 4.6 points, indicating that, on average, a meaningful improvement in fatigue had occurred. After 16 weeks, the mean score improved by 6.8 points, indicating substantial improvement in fatigue on average. On an individual patient basis, 61% of patients in the study experienced a clinically important reduction in fatigue after treatment with darbepoetin alfa (Vadhan-Raj et al.) .
As shown in Figure 2 , improvement in fatigue is associated closely with increases in hemoglobin, such that the greatest 
Study week
Note. Hemoglobin values within 28 days of a red blood cell transfusion were excluded; other missing data were not input (available data method). Observations were taken at the end of the week, indicated in the x axis (i.e., week 4 is after four weeks on study or after two doses of the study drug).
relief in fatigue occurred in patients with the highest increase in hemoglobin Vadhan-Raj et al., 2003) . Of note, patients did not need to have moderate to severe anemia (hemoglobin < 10.0 g/dl) to experience a reduction in fatigue; even patients with only mild anemia (hemoglobin > 10.0 g/dl) at baseline had noticeable improvements in their fatigue symptoms.
Energy Level
Energy levels were assessed in patients treated with darbepoetin alfa Q2W using the Energy Numerical Rating Grade, a self-reported visual analog scale developed for use in studies of darbepoetin alfa. Patients record their energy levels over the previous four weeks on a scale of 1-10 (Vadhan-Raj et al., 2003) . The score then was converted to a 0-100 scale to allow comparisons with published results of similar scales. Mean increases from baselines of 7.3 and 12.5 points, respectively, from a mean baseline score of 45.4 points were observed after 8 and 16 weeks of treatment with darbepoetin alfa. Thus, patients treated with darbepoetin alfa experienced an improvement in their energy levels of almost 30% on average after 16 weeks.
Symptom Burden
In the study of darbepoetin alfa administered as a fi xed dose of 200 mcg Q2W, a new tool for assessing the impact of symptoms in patients with cancer, the M.D. Anderson Symptom Inventory was used (Cleeland et al., 2000) . This also was developed and validated to measure symptom severity and its interference with functional capacity; it includes 19 questions, 13 relating to core symptoms and 6 to symptom interference with life activities. Five symptoms thought to be associated with anemia (fatigue, distress, sleep disturbances, lack of appetite, and pain) were prespecifi ed for analysis in the protocol. In an interim analysis, change in these symptoms after 12 weeks of treatment with darbepoetin alfa was analyzed (Cleeland et al., 2003) . Fatigue, distress, sleep disturbance, and lack of appetite scores all improved from baseline, indicating decreased symptom severity. Analysis of the fatigue scores by change in hemoglobin suggests that improvement in fatigue was related strongly to an increase in hemoglobin levels.
Safety of Darbepoetin Alfa Every Two Weeks
Darbepoetin alfa Q2W has been well tolerated in clinical studies, with the reported adverse events typical for a population of patients with cancer receiving chemotherapy (Glaspy & Tchekmedyian, 2002; Kotasek et al., 2003; Vadhan-Raj et al., 2003; Vansteenkiste et al., 2002) . In an open-label study of patients with nonmyeloid malignancies, the only adverse event considered to be related to treatment and occurring in more than 1% of patients was injection-site pain (in 2% of patients) (Vadhan-Raj et al.) . No antibodies to darbepoetin alfa have been detected in clinical studies, and no clinical symptoms or sequelae suggesting the presence of neutralizing antibodies have been observed Kotasek et al.; Vansteenkiste et al., 2002) . The safety profi les of darbepoetin alfa and epoetin alfa are similar (Amgen Inc., 2002; Mirtsching et al., 2003) . No detriment to survival or disease progression has been reported to date in clinical trials of darbepoetin alfa (Hedenus et al., 2003; Vansteenkiste et al., 2002; Vansteenkiste, Tomita, Rossi, & Pirker, 2004) .
Comparison of Darbepoetin Alfa Every Two Weeks and Epoetin Alfa
Epoetin alfa is used widely to treat chemotherapy-induced anemia in patients with cancer and is effective in increasing hemoglobin levels, decreasing transfusion requirements, and improving energy levels and QOL (Buchsel et al., 2002; Cella, 2002; Crawford et al., 2002; Demetri et al., 1998; Gabrilove et al., 2001; Glaspy et al., 1997; Littlewood et al., 2001; Quirt et al., 2001) . Nurses should understand how darbepoetin alfa administered Q2W compares with epoetin alfa in terms of efficacy and convenience to patients and their caregivers. The relative cost of the two treatments also is of interest, as it may be a factor when healthcare providers are considering the options for anemia management.
Comparison of Hematologic Effi cacy
Darbepoetin alfa Q2W demonstrated similar effi cacy to the epoetin alfa QW control group in an early dose-fi nding study (see Table 1 ) (Glaspy & Tchekmedyian, 2002) . Because this comparison was based on small numbers of patients, Mirtsching et al. (2003) performed a larger analysis combining data from three studies of darbepoetin alfa to obtain a larger sample size for comparison. The meta-analysis confirmed the similar efficacy and safety of darbepoetin alfa at a starting dose of 3.0 mcg/kg Q2W (N = 1,206) and epoetin alfa at a starting dose of 150 U/kg TIW or 40,000 U QW (N = 115). Both treatments had a similar rate of RBC transfusion: 15% for the darbepoetin alfa group and 14% for the epoetin alfa group. The results of the large, community-based study of darbepoetin alfa Q2W (Amgen Inc., data on fi le; Vadhan-Raj et al., 2003) also can be benchmarked against results of similarly designed studies of epoetin alfa given TIW or QW (Demetri et al., 1998; Gabrilove et al., 2001; Glaspy et al., 1997 ) (see Table 2 ). Hemoglobin response, hematopoietic response, change in hemoglobin, and incidence of transfusions were similar for darbepoetin alfa and epoetin alfa across all studies.
To directly analyze the similar fi ndings seen with darbepoetin alfa Q2W and epoetin alfa QW treatment regimens, three comparative trials have been conducted, each in patients with a specifi c tumor type (breast, lung, or gynecologic cancer). In the trials, anemic patients (hemoglobin < 11.0 g/dl) were randomized in a 1:1 ratio to receive either darbepoetin alfa 200 mcg Q2W or epoetin alfa 40,000 U QW for as long as 16 weeks. Dose increases to 300 mcg Q2W for darbepoetin alfa and 60,000 U QW for epoetin alfa were allowed for patients who did not have at least a 1.0 g/dl increase in hemoglobin after four weeks of treatment. Final analysis of data from pooled fi ndings of the three studies suggests that both treatment regimens appear to achieve comparable outcomes (Schwartzberg et al., 2004) . The mean change in hemoglobin from baseline to the end of treatment was 1.4 g/dl for patients receiving darbepoetin alfa and 1.5 g/dl for those receiving epoetin alfa, with a similar proportion of patients in both treatment groups requiring an RBC transfusion during the study (16% and 17%, respectively) Data on the effects of the two agents on QOL in these comparative studies have not yet been published. However, the studies were designed to validate the Patient Satisfaction Questionnaire for Anemia (PSQ-An) tool. This was found to be valid, feasible, and reliable, although future studies need to be conducted with the PSQ-An to assess the impact of anemia on patients and caregivers.
A line of evidence supporting the comparable hematologic effects of the two agents comes from recent retrospective chart reviews of patients with chemotherapy-induced anemia treated at hospitals and community centers throughout the United States (Boccia et al., 2003; Reeves et al., 2003; Schwartzberg et al., 2003) . The chart reviews indicated that the most common doses of the two agents used in community practice (darbepoetin alfa 200 mcg Q2W and epoetin alfa 40,000 U QW) are associated with similar changes in hemoglobin and similar rates of RBC transfusion, with a similar frequency of dose increase.
Relative Cost of Darbepoetin Alfa and Epoetin Alfa
To examine and compare the costs associated with two therapies of equivalent effectiveness, a cost-minimization analysis can be performed (Bootman, Townsend, & McGhan, 1996) . A simple cost-minimization model was designed (see Table 3 ) using assumptions based on the data from Schwartzberg et al.'s (2003) retrospective chart review. Costs related to treatment are based only on acquisition costs and are calculated using the average wholesale prices for both products: $4.99 per mcg for darbepoetin alfa and $13.36 per 1,000 units for epoetin alfa, from the December 2003 Red Book (Red Book TM , 2003) . Assuming that the effectiveness of darbepoetin alfa 200 mcg Q2W and epoetin alfa 40,000 U QW are the same, and that a dose escalation occurs for both treatments in 15% of patients at week 7 (to darbepoetin alfa 300 mcg Q2W or epoetin alfa 60,000 U QW), the average cost savings over 16 weeks of therapy using darbepoetin alfa for 100 patients, based on the model, would be $592.95, or approximately 7%. 
Discussion Erythropoietic Therapy Improves Quality of Life
A discernible need exists to treat anemia in patients receiving chemotherapy. Management of chemotherapy-induced anemia has been shown to be one of only two interventions that have consistent, positive effects on patients' fatigue levels (the other is aerobic exercise) (Nail, 2002) . The use of erythropoietic agents improves patients' overall health-related QOL, by decreasing fatigue and increasing energy levels, as cited in the studies reviewed for this article. In an analysis of data from two additional clinical trials in which patients with chemotherapy-induced anemia were treated with erythropoietic therapy, a clinically important reduction in fatigue (as measured by the FACT-F questionnaire) was associated with a reduction in levels of depression and anxiety (Amorajabi, Tchekmedyian, & Kallich, 2003; Tchekmedyian, Kallich, McDermott, Fayers, & Erder, 2003) .
Benefi ts of Less-Frequent Dosing of Erythropoietic Agents
Patients with cancer receive multiple treatments for the primary disease and as supportive therapy. However, frequent clinic visits to receive treatment may be a burden for patients and caregivers. The time and expense involved may mean that patients have to take leave from work, change or cancel social functions, and neglect household responsibilities. Often, diffi culties with transportation are cited in connection with clinic visits (Haithcox, Ramnes, Lee, Lu, & Lyman, 2003; Moore, 2002) . Out-of-pocket expenses are an added burden (Meehan et al., 2002) . Anemic patients experiencing fatigue may fi nd frequent clinic visits particularly taxing because they place an extra burden on already-depleted energy levels (Moore, Fortner, & Okon, 2003) . Frequent visits may have psychological effects, reinforcing patients' self-perception as "patients with cancer" and causing increased anxiety and even depression (Moore; Moore et al.) . Caregivers also may be placed under additional strain; for example, they may need to take repeated time off work to accompany patients to the clinic (Moore; Haithcox et al.) .
Those closely involved with patients are likely to appreciate the advantages of treatment that reduces the number of injections, as long as the effectiveness of the treatment is not impaired. Patients also indicate this preference. In an observational study of patients with cancer receiving supportive therapy, most patients expressed a wish for longer-acting treatment that would require fewer injections (Haithcox et al., 2003) . Recent data also have confi rmed that the use of long-acting growth factors to treat cancer-associated anemia and neutropenia results in signifi cant time savings for clinic staff as a consequence of fewer clinic visits required (Beveridge et al., 2003) .
Role of Nurses in Anemia Management
Given the impact of multiple clinic visits, a need exists to minimize the number of trips required for cancer treatment and its associated complications, when possible, to optimize patients' QOL. Many visits may be solely to receive supportive therapy (Haithcox et al., 2003) , so a treatment for anemia that permits less-frequent dosing clearly is desirable. As indicated in this review, darbepoetin alfa appears to offer the opportunity to manage anemia in patients with cancer effectively and with fewer clinic visits, without adversely affecting the effi cacy of hematopoietic supportive care.
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